Brief: Newron Announces Results Of Explanatory Studies With Evenamide
01/04/2021 06:04
April 1 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* NEWRON ANNOUNCES RESULTS OF EXPLANATORY STUDIES WITH
EVENAMIDE
IN HEALTHY VOLUNTEERS AND PATIENTS WITH SCHIZOPHRENIA
* PRIMARY OBJECTIVE OF SAFETY OF EVENAMIDE MET ON ALL SAFETY
VARIABLES FOR STUDY 010 IN HEALTHY VOLUNTEERS AND STUDY 008 IN
PATIENTS WITH SCHIZOPHRENIA
* ADDITIONAL SAFETY AND EFFICACY STUDY 008A IN THERAPEUTIC
DOSE
(30 MG BID) TO START IN APRIL 2021
Source text for Eikon: ID:nEQHMBjla
Further company coverage: NWRN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study